Eicosanoid Synthesis and Function

Eicosanoids are pivotal signaling molecules that orchestrate your body's inflammatory and immune responses. Understanding their synthesis and function is essential not only for grasping fundamental physiology but also for clinical applications, as they are the targets of widely used medications like aspirin and ibuprofen. On the MCAT, this topic frequently appears in the Biological and Biochemical Foundations section, requiring you to integrate knowledge of biochemistry, pharmacology, and pathology.

Eicosanoids: Signaling Lipids from Arachidonic Acid

Eicosanoids are a large family of potent, hormone-like signaling lipids that act locally near their site of synthesis. They are not stored in cells but are synthesized on demand from a 20-carbon polyunsaturated fatty acid called arachidonic acid. This precursor is esterified and stored in the sn-2 position of membrane phospholipids. Upon a cellular stimulus—such as tissue injury, hormonal signal, or immune challenge—the enzyme phospholipase A2 (PLA2) is activated. PLA2 hydrolyzes the phospholipid, releasing arachidonic acid into the cytoplasm, where it becomes the substrate for two major enzymatic pathways. Think of the cell membrane as a reservoir; PLA2 is the tap that releases the raw material (arachidonic acid) for rapid eicosanoid production. This immediate release system allows for a swift, localized response to insult, which is a classic MCAT concept linking cell signaling to physiological outcomes.

The Cyclooxygenase Pathway: Mediators of Inflammation and Hemostasis

Once freed, arachidonic acid can be metabolized by the cyclooxygenase (COX) enzyme. COX exists in two primary isoforms: COX-1, which is constitutively active in most tissues for "housekeeping" functions, and COX-2, which is inducible at sites of inflammation. COX catalyzes two reactions: first, it adds two oxygen molecules to arachidonic acid to form the unstable intermediate PGG2, then it reduces it to PGH2. PGH2 is the central branch point for the synthesis of specific prostaglandins (e.g., PGE2, PGI2) and thromboxanes (primarily TXA2).

Each of these molecules has distinct, powerful effects:

• Prostaglandins like PGE2 are key mediators of inflammation, pain, and fever. They cause vasodilation, increase vascular permeability, and sensitize nerve endings to pain stimuli.
• Prostacyclin (PGI2) is a vasodilator and inhibits platelet aggregation.
• Thromboxane A2 (TXA2) promotes vasoconstriction and stimulates platelet aggregation, playing a crucial role in hemostasis.

Consider a patient with a sprained ankle: the localized swelling, redness, heat, and pain are direct results of prostaglandin action. For the MCAT, you must understand the contradictory roles of PGI2 and TXA2 in vascular tone and platelet function—a common source of trap questions. The exam often tests that an imbalance (e.g., too much TXA2) can predispose to thrombosis.

The Lipoxygenase Pathway: Leukotrienes and Respiratory Responses

The alternative major pathway for arachidonic acid involves the lipoxygenase (LOX) family of enzymes, most notably 5-lipoxygenase. This enzyme, often found in inflammatory cells like neutrophils, mast cells, and macrophages, adds a hydroperoxy group to arachidonic acid to form 5-HPETE. This is subsequently converted into leukotrienes. Leukotrienes (such as LTB4, LTC4, LTD4) are potent mediators of allergic and inflammatory reactions, historically known as the "slow-reacting substance of anaphylaxis."

Their primary functions include:

• Chemotaxis: LTB4 attracts neutrophils and other white blood cells to the site of inflammation.
• Bronchoconstriction: LTC4, LTD4, and LTE4 cause powerful constriction of bronchial smooth muscle.
• Increased Vascular Permeability: They promote leakage from post-capillary venules, contributing to edema.

A classic clinical vignette involves an asthma attack: allergen exposure triggers mast cells to release leukotrienes, leading to wheezing, shortness of breath, and mucus production. On the MCAT, you should be able to connect this pathophysiology to drug classes like leukotriene receptor antagonists (e.g., montelukast), which are a mainstay in asthma management.

Therapeutic Inhibition with NSAIDs

Given their central role in inflammation and pain, the eicosanoid pathways are prime pharmacological targets. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, naproxen, and aspirin, work by inhibiting the cyclooxygenase enzymes. By blocking COX, NSAIDs prevent the formation of prostaglandins and thromboxanes from arachidonic acid, thereby reducing inflammation, pain, and fever.

This mechanism has critical clinical nuances:

• Non-selective NSAIDs (e.g., ibuprofen) inhibit both COX-1 and COX-2. While effective, their inhibition of gastric COX-1 (which produces prostaglandins that protect the stomach lining) can lead to side effects like gastritis and ulcers.
• COX-2 selective inhibitors (e.g., celecoxib) were designed to minimize GI toxicity but carry an increased risk of cardiovascular events, partly due to an imbalance between pro-thrombotic TXA2 and anti-thrombotic PGI2.
• Aspirin is unique: it irreversibly acetylates COX-1 in platelets, permanently shutting down TXA2 production for the platelet's lifespan (7-10 days). This underlies its use as an antiplatelet therapy for cardiovascular prevention.

When approaching MCAT questions on pharmacology, reason step-by-step: identify the target pathway (COX), the inhibited products (prostaglandins), and the resulting physiological effect (reduced inflammation). A common trap is confusing NSAIDs with steroids; corticosteroids work upstream by inhibiting phospholipase A2, providing a broader anti-inflammatory effect.

Common Pitfalls

1. Confusing the Pathways and Their Products: It's easy to mix up which enzyme makes which mediators. Remember: COX leads to prostaglandins and thromboxanes; LOX leads to leukotrienes. A helpful mnemonic is "COX for Pain and Clots" (prostaglandins for pain, thromboxanes for clots) and "LOX for Lungs and Leukocytes."
2. Overlooking the Dual Roles of Prostaglandins: Not all prostaglandin effects are pathological. For example, PGE2 in the stomach promotes mucus and bicarbonate secretion, protecting the mucosa. Inhibiting this "good" prostaglandin is why NSAIDs cause GI upset. Always consider context.
3. Misunderstanding Aspirin's Unique Action: Aspirin is not just another NSAID for the MCAT. Its irreversible, covalent inhibition of COX-1 in anucleated platelets is a high-yield distinction. This is why its antiplatelet effect lasts for days, unlike reversible inhibitors like ibuprofen.
4. Forgetting the Cellular Source: Eicosanoids are not made by one "gland" and transported; they are synthesized locally by many cell types (e.g., macrophages, endothelial cells, platelets) in response to local stimuli. This autocrine and paracrine signaling is a key conceptual point.

Summary

• Eicosanoids are locally-acting signaling lipids synthesized on demand from arachidonic acid, which is released from cell membranes by the enzyme phospholipase A2.
• The cyclooxygenase (COX) pathway converts arachidonic acid into prostaglandins (mediators of inflammation, pain, fever, and gastric protection) and thromboxanes (promoters of vasoconstriction and platelet aggregation).
• The lipoxygenase (LOX) pathway produces leukotrienes, which are crucial in allergic responses and cause bronchoconstriction, chemotaxis, and increased vascular permeability.
• NSAIDs exert their therapeutic effects by inhibiting COX, thereby reducing the production of pro-inflammatory prostaglandins and thromboxanes.
• For clinical and exam success, you must understand the specific roles of different eicosanoids, the consequences of inhibiting their synthesis, and the unique pharmacology of drugs like aspirin.